 The proposed settlement with bankrupt Purdue Pharma would have resolved thousands of lawsuits over its marketing and sales of OxyContin. The deal was set to be worth about $10 billion, $6 billion of which would come from members of the Sackler family, Purdue's owners. In exchange, the Sacklers, who have not declared bankruptcy themselves, would have gained immunity from opioid-related lawsuits.